Vinomis Featured in Larchmont Chronicle (Los Angeles)

Los Angeles, CA, September 5, 2009 - Vinomis Marketing Vice President Barry Yarkoni described the background and science behind Vindure 900, and explained what consumers should look for (and beware of) when purchasing a Resveratrol based supplement.

Vinomis Launches New Learning Center for Resveratrol, Red Wine Grape Extracts, Antioxidants and Polyphenols Information

Pittsburgh, PA, August 17, 2009 - Vinomis Has launched its learning center - a comprehensivesource of information about a broad range of subjects surrounding Resveratrol, polyphenols, antioxidants, and Red Wine grapes and extracts. Topics include basic science, scientific studies, medical benefits, foods, and dietary supplements. In addition, Vinomis has launched its FORUM where users can openly share thoughts, experiences, and advice on a broad range of medical topics.

Brunswick Labs Certifies Antioxidant Power of Vindure 900 from Vinomis Laboratories

Pittsburgh, PA, July 21, 2009 - Brunswick Laboratories, the leader in antioxidant testing of foods and supplements, has determined that each Vindure 900 tablet from Vinomis Laboratories has an ORAC rating of 19,638, over six times times the USDA recommended daily consumption of at least 3000 ORAC units.

Vinomis Introduces Vindure 900 - The Resveratrol-equivalent of Over 100 Bottles of Red Wine Plus Quercetin and Red Wine Grape Extract

Pittsburgh, PA, July 9, 2009 - Vinomis Laboratories today introduced a new super-concentrated dietary supplement based on a 900mg combination of three widely acclaimed ingredients: 98% Pure Resveratrol, Red Wine Grape Extract, and Quercetin in a one-per day tablet. This is the first product to be based on proprietary science developed at Harvard Medical School, and licensed to Vinomis. In addition to the long-term health benefits, over 90% of customers are reporting increased energy, improved endurance, improved mental acuity, improved blood sugar, or weight loss.

Xenomis LLC Signs Licensing Agreement With Harvard Medical School for Technology to Assist in the Development of Nutraceutical Products Based Upon Proprietary Stressed Plant Science

Pittsburgh, PA, October 23, 2007 - Xenomis LLC announced today it has signed an exclusive licensing agreement with Harvard Medical School for proprietary science that will assist in the development of nutraceutical products with potentially far reaching physiological benefits. Under the terms of the agreement, Harvard will receive downstream royalties and equity.